Physician profile
Stephen Reale
NPI 1396846572
$4,070.57
in general payments reported to CMS, 2019-2025
40 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $246 · 2021: $396 · 2022: $402 · 2023: $462 · 2024: $932 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.38 | 2019-2025 | |
| Amgen INC. | $412.67 | 2019-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $282.82 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $209.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Philips North America LLC | $197.64 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.52 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $193.74 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $184.30 | 2024-2025 | Airsupra, Breztri |
| Vanda Pharmaceuticals INC. | $147.37 | 2019-2025 | Fanapt |
| Glaxosmithkline, LLC. | $145.89 | 2022-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.33 | 2025 | Caplyta |
| Pfizer INC. | $130.91 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $95.20 | 2025 | |
| Merck Sharp & Dohme LLC | $94.41 | 2019-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $78.82 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Reale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.